Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic RSK1 Targeting in Myeloid Malignancies
NCT07379125Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PMD-026 in myelofibrosis (MF), myelodysplastic syndrome (MDS) and Myeloproliferative Neoplasm (MPN) (7 arms), sponsored by Washington University School of Medicine. Primary endpoints: Adverse Events, Dose Limiting Toxicities and 4 more. Started May 2026; status: recruiting.
02
Drugs
PMD-026
03
Conditions
myelofibrosis (MF)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT07379125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07379125.